Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
202.19
+1.57 (0.78%)
At close: Jul 24, 2026, 4:00 PM EDT
201.80
-0.39 (-0.19%)
After-hours: Jul 24, 2026, 7:40 PM EDT
Biogen Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 9,937 | 9,891 | 9,676 | 9,836 | 10,173 | 10,982 |
Revenue Growth | 1.23% | 2.22% | -1.62% | -3.32% | -7.36% | -18.32% |
Gross Profit Gross Profit Growth | 7,502 | 7,486 | 7,366 | 7,302 | 7,895 | 8,872 |
Operating Income Operating Income Growth | 1,933 | 1,862 | 2,250 | 1,612 | 3,484 | 2,841 |
Net Income Net Income Growth | 1,372 | 1,293 | 1,632 | 1,161 | 2,962 | 1,728 |
Earnings Per Share EPS Growth | 9.32 | 8.79 | 11.18 | 7.97 | 20.87 | 10.40 |
EPS Growth | -8.00% | -21.38% | 40.28% | -61.81% | 100.67% | -58.06% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Multiple Sclerosis Product Multiple Sclerosis Product Growth | 4,043 | 4,039 | 4,350 | 4,662 | 5,430 | 6,097 |
Rare Disease Product Rare Disease Product Growth | 2,148 | 2,154 | 1,988 | 1,803 | 1,794 | 1,905 |
Biosimilars Product Biosimilars Product Growth | 730.5 | 729.1 | 793.1 | 770 | 751.1 | 831.1 |
Other Product Other Product Growth | 223.2 | 197.2 | 82.5 | 11.8 | 13 | 14 |
Revenue (Total) Revenue (Total) Growth | 9,937 | 9,891 | 9,676 | 9,836 | 10,173 | 10,982 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 4,748 | 3,816 | 2,375 | 1,050 | 4,893 | 3,803 |
Total Debt Total Debt Growth | 6,562 | 6,577 | 6,630 | 7,338 | 6,614 | 7,604 |
Net Cash (Debt) Net Cash Growth | -1,814 | -2,762 | -4,255 | -6,288 | -1,721 | -3,801 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -12.32 | -18.77 | -29.17 | -43.19 | -11.79 | -25.41 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 2,591 | 2,205 | 2,876 | 1,547 | 1,384 | 3,640 |
Capital Expenditures CapEx Growth | -167.9 | -153.8 | -153.7 | -277 | -240.3 | -258.1 |
Free Cash Flow Free Cash Flow Growth | 2,423 | 2,051 | 2,722 | 1,270 | 1,144 | 3,382 |
Free Cash Flow Growth | -0.57% | -24.65% | 114.28% | 11.03% | -66.17% | -11.12% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 75.49% | 75.69% | 76.12% | 74.24% | 77.61% | 80.79% |
Operating Margin | 19.45% | 18.83% | 23.25% | 16.39% | 34.24% | 25.87% |
Pretax Margin | 16.33% | 15.74% | 19.70% | 13.18% | 35.31% | 15.89% |
Profit Margin | 13.81% | 13.07% | 16.87% | 11.81% | 29.11% | 15.73% |
FCF Margin | 24.38% | 20.73% | 28.13% | 12.91% | 11.24% | 30.79% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 21.75 | 20.02 | 13.68 | 32.47 | 13.27 | 23.07 |
Forward PE | 17.12 | 13.66 | 9.71 | 17.54 | 17.70 | 13.94 |
P/FCF Ratio | 12.32 | 12.59 | 8.19 | 29.52 | 34.88 | 10.43 |
PS Ratio | 3.00 | 2.61 | 2.30 | 3.81 | 3.92 | 3.21 |